Irwin Matthew P, Yu Yang, Turner Catherine E, Ooi Kevin C, Morgan Matthew J
Department of Colorectal Surgery, Bankstown-Lidcombe Hospital, Sydney, Australia.
School of Clinical Medicine, University of New South Wales, Sydney, Australia.
Int J Colorectal Dis. 2025 Apr 2;40(1):84. doi: 10.1007/s00384-025-04870-5.
Sacral neuromodulation (SNM) is an established treatment for faecal incontinence. This study analyses patient experience with SNM beyond quality of life and incontinence scores to better understand patient expectations and improve patient selection.
Patients receiving SNM for faecal incontinence at three Australian sites from 2013 to 2023 were subject to cohort analysis. St. Mark's Incontinence Score (SMIS) and Rapid Assessment of Faecal Incontinence Score (RAFIS) assessed incontinence and quality of life. Thematic analysis of structured interviews qualitatively assessed patient experience.
Seventy-one patients aged 52-86 years (M = 69) experienced SNM and 56 agreed to interview at median 6-year post-procedure. Forty-five (63%) proceeded to permanent SNM and progression was not influenced by age, sex, culture, insurance status or presence of anal sphincter defect. Thirty-nine (87%) retained their neuromodulator with battery life M = 6.5 years, 95% CI [5.2, 7.8]. Permanent SNM improved incontinence (P < 0.01) and quality of life (P < 0.01). Forty-eight (86%) patients desired 30-min education pre- and post-procedure. Thirty-seven (86%) desired follow-ups at 1 month, 12 months and at battery depletion. Twenty (36%) had initial reservations which resolved in all but one patient. Twenty-one (54%) remained dependent on others for neuromodulator customisation and this dependence increased with age (P = 0.02). Fifty (89%) recommend SNM to others, despite 8 (14%) regretting their personal experience.
SNM continues to improve faecal incontinence and quality of life. Initial reservations usually resolve and most patients recommend it to others. While adequate patient education and follow-up is not onerous to achieve, most patients remain dependent for neuromodulator customisation.
骶神经调节(SNM)是一种已确立的治疗大便失禁的方法。本研究分析了患者在SNM治疗方面的体验,超越了生活质量和失禁评分,以更好地了解患者的期望并改善患者选择。
对2013年至2023年在澳大利亚三个地点接受SNM治疗大便失禁的患者进行队列分析。圣马克失禁评分(SMIS)和大便失禁快速评估评分(RAFIS)用于评估失禁情况和生活质量。通过对结构化访谈进行主题分析,定性评估患者的体验。
71名年龄在52 - 86岁(中位数M = 69岁)的患者接受了SNM治疗,56名患者同意在术后中位数6年时接受访谈。45名(63%)患者进行了永久性SNM治疗,治疗进展不受年龄、性别、文化、保险状况或肛门括约肌缺陷的影响。39名(87%)患者保留了神经调节器,电池寿命中位数M = 6.5年,95%置信区间为[5.2, 7.8]。永久性SNM改善了失禁情况(P < 0.01)和生活质量(P < 0.01)。48名(86%)患者希望在术前和术后接受30分钟的教育。37名(86%)患者希望在术后1个月、12个月和电池耗尽时进行随访。20名(36%)患者最初有所保留,但除一名患者外其他患者的保留意见均已消除。21名(54%)患者在神经调节器定制方面仍依赖他人,且这种依赖程度随年龄增长而增加(P = 0.02)。50名(89%)患者向他人推荐SNM,尽管有8名(14%)患者对自己的治疗经历感到后悔。
SNM持续改善大便失禁情况和生活质量。最初的保留意见通常会消除,大多数患者会向他人推荐。虽然实现充分的患者教育和随访并不困难,但大多数患者在神经调节器定制方面仍依赖他人。